Abstract
Objective Evaluation of quantification capabilities at ultra-low radiation dose levels of a first-generation dual-source Photon-Counting Computed Tomography (PCCT) compared to a dual-source dual-energy CT (DECT) scanner.
Methods A multi-energy CT phantom was imaged with and without extension ring on both scanners over a range of radiation dose levels (CTDIvol 0.4 - 15.0 mGy). Scans were performed in different modes of acquisition for PCCT with 120 kVp and DECT with 70/Sn150 kVp and 100/Sn150 kVp. Various tissue inserts were used to characterize the precision and repeatability of Hounsfield Units (HUs) on virtual mono-energetic images between 40 and 190 keV. Image noise was additionally investigated at ultra-low radiation dose to illustrate PCCT’s ability to remove electronic background noise.
Results Our results demonstrate high precision of HU measurements for a wide range of inserts and radiation exposure levels with PCCT. We report high performance for both scanners across a wide range of radiation exposure levels with PCCT outperforming at low exposures compared to DECT. PCCT scans at lowest radiation exposures illustrate significant reduction in electronic background noise, with a mean percent reduction of 74% (p-value ∼10−8) compared to the 70/Sn150 kVp and 60% (p-value ∼10−6) compared to the 100/Sn150 kVp.
Conclusions This paper reports first experiences with a clinical dual-source PCCT scanner with Quantum technology. PCCT provides reliable HUs without disruption from electronic background noise for a wide range of dose values. Diagnostic benefits are not only for quantification at ultra-low-dose but also for imaging of obese patients.
Key Points
PCCT scanners with Quantum technology provide precise and reliable quantitative Hounsfield Units at ultra-low-dose levels.
Influence of electronic background noise can be removed at ultra-low dose acquisitions with PCCT.
Both spectral platforms have high performance along a wide range of radiation exposure levels with PCCT outperforming at low radiation exposures.
Competing Interest Statement
Harold I. Litt, Peter B. Noël, and Mitch Schnall have a research agreement with Siemens Healthineers. Pooyan Sahbaee is an employee of Siemens Healthineers.
Funding Statement
This study was funded by the National Institutes of Health (R01EB030494).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
